NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment

Pathology International - Tập 68 Số 11 - Trang 583-595 - 2018
Christopher A. French1
1Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Tóm tắt

NUT carcinoma (NC) is a rare, aggressive subtype of squamous cell carcinoma defined by rearrangement of the NUTM1 (aka NUT) gene. NC is driven by NUT‐fusion oncoproteins resulting from chromosomal translocation, most commonly BRD4‐NUT. This is a nearly uniformly lethal cancer affecting patients of all ages, but predominantly teens and young adults. The cell of origin is unknown, but NC most commonly arises within the thorax and head and neck. NC typically consists of sheets of monomorphic primitive round cells that can exhibit focal abrupt squamous differentiation. Diagnosis of NC is easy, and can be established by positive NUT nuclear immunohistochemical staining. Though characterization of the NUTM1‐fusion gene is desirable by molecular analysis, it is not required for the diagnosis. The increasingly widespread availability of the NUT diagnostic test is leading to increasing diagnoses of this vastly underdiagnosed disease. The NUT midline carcinoma registry (www.NMCRegistry.org) serves as a central repository that has provided the main source of clinical and outcomes data for NC. Currently there is no effective therapy for NC, however small molecules directly targeting the BRD4 portion of BRD4‐NUT, termed BET bromodomain inhibitors, have shown activity.

Từ khóa


Tài liệu tham khảo

Kubonishi I, 1991, Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma, Cancer Res, 51, 3327

10.1097/00043426-199124000-00011

10.1002/1097-0142(19931001)72:7<2273::AID-CNCR2820720735>3.0.CO;2-U

10.1002/1097-0142(20010901)92:5<1195::AID-CNCR1438>3.0.CO;2-3

10.1002/ijc.2910500216

French CA, 2003, Fletcher JA BRD4‐NUT fusion oncogene: A novel mechanism in aggressive carcinoma, Cancer Res, 63, 304

10.1200/JCO.2004.02.107

French CA, 2015, NUT Carcinoma, 412

10.1146/annurev-pathol-011811-132438

10.1158/1078-0432.CCR-12-1153

10.1002/cncr.30242

10.1097/JTO.0000000000000545

10.1007/s12105-010-0174-6

10.1097/PAS.0b013e3181abe120

10.1007/s12105-010-0174-6

10.2350/09-10-0727-CR.1

10.1097/PAS.0000000000001021

10.1002/cncy.21761

10.1002/pbc.20755

10.1080/08880018.2017.1363839

10.1038/ng.3230

10.1126/science.1208130

10.1038/nature14129

10.1038/nm0797-730

10.1016/j.cell.2004.06.006

10.1016/j.ceb.2005.08.001

10.1038/nrm1835

10.1093/annonc/mdw686

10.1038/onc.2012.487

10.1038/oncsis.2015.33

10.1016/j.molcel.2005.06.029

10.1073/pnas.0705053104

10.1128/MCB.01020-07

10.1038/sj.onc.1210852

10.1158/2159-8290.CD-14-0014

10.1073/pnas.1702086114

10.1158/1541-7786.MCR-18-0474

10.1002/gcc.3

Gatalica ZSJ, 2018, NUTM1 gene rearranged neoplasia, Lab Invest, 98, 698

10.1038/ncomms13331

10.1016/j.ebiom.2016.04.038

10.1038/ncomms11790

10.1038/ng.3909

10.1016/j.cell.2016.01.015

10.1200/JCO.2018.36.15_suppl.6085

10.1097/PAS.0b013e318258f03b

10.1097/PAS.0b013e31815a3900

10.1097/PAP.0b013e31819923e4

10.1002/dc.21134

10.1097/01.COC.0000020960.98562.84

10.1097/JTO.0b013e3182460f8f

10.1007/s12105-012-0363-6

10.1016/S0968-6053(03)00069-3

10.1097/PAS.0b013e318198d666

ChirieacLR FrenchCA ShollL YatabiY. WHO (2015) Classification of Tumours of the Lung. 4 ed. In Travis WD Brambilla E Burke AP Marx A Nicholson AG editor.Herndon VA:Stylus Publishing LLC;2015;2.

10.1097/PAS.0b013e31824230a8

10.1186/1471-2407-6-69

10.1586/14737140.2015.1082909

10.1097/PAS.0b013e318254ce54

10.1007/s12105-013-0496-2

10.1097/PAI.0b013e3182a4ef2e

10.3322/caac.21387

10.1038/nature12147

10.1073/pnas.1433065100

10.1038/onc.2013.126

10.1128/MCB.01341-10

10.1016/j.molcel.2005.06.027

10.1074/jbc.M111.282855

10.1016/j.cell.2013.03.036

10.1038/nm.3665

10.1158/1078-0432.CCR-15-1449

10.1038/emboj.2010.176

10.1074/jbc.M114.600759

10.18632/oncotarget.22862

10.1158/0008-5472.CAN-10-3513

10.1101/gad.267583.115

10.1016/S0959-8049(00)00028-9

10.1038/nature09504

10.1038/nature10334

10.1073/pnas.1108190108

10.1073/pnas.1216363109

10.1158/2159-8290.CD-12-0418

10.1016/j.ccr.2013.11.003

10.1158/1078-0432.CCR-12-3904

10.1038/nature13229

10.1016/j.ccr.2014.01.028

10.1158/1535-7163.MCT-13-0770

10.1158/1078-0432.CCR-14-1561

10.1038/onc.2015.126

10.1038/nature16508

10.1158/2159-8290.CD-15-1335

O'Dwyer PJ, 2016, Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: Results from part 1 of a phase I/II open‐label single‐agent study in patients with NUT midline carcinoma (NMC) and other cancers, Cancer Res, 76

Lewin J, 2018, Phase Ib trial with birabresib, a small‐molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors, J Clin Oncol

10.1016/S2352-3026(16)00021-1

10.1016/S2352-3026(15)00247-1

10.1016/j.celrep.2017.08.082

10.1038/bjc.2014.54

10.1002/pbc.25350

10.1158/1535-7163.MCT-16-0390

Thông tin
Thông tin xuất bản

Pathology International

Tập 68 Số 11

583-595

Thông tin tác giả